Celldex $300M Public Offering Priced
Analysis based on 6 articles · First reported Apr 01, 2026 · Last updated Apr 02, 2026
The public offering by Celldex Therapeutics is expected to provide significant capital, which could positively impact its stock price by funding commercial readiness and clinical development of its product candidates. The involvement of several financial institutions as managers indicates market confidence in the offering.
Celldex Therapeutics announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at $29.00 per share, aiming to raise approximately $300 million. The company plans to use these proceeds to fund commercial readiness activities for barzolvolimab, continue clinical and preclinical development of its product candidates, grow its bispecific antibody platform, and for general corporate purposes. Leerink Partners, Toronto-Dominion Bank — TD Cowen, Guggenheim Partners, and Cantor Fitzgerald are acting as joint bookrunning managers, with LifeSci Capital and H.C. Wainwright & Co. as co-lead managers. The offering is expected to close around April 6, 2026, and is being made pursuant to a shelf registration statement filed with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard